Daniel R. Anderson, M.D., Ph.D

Assistant Professor
Division of Cardiology

Academic office:
Department of Internal Medicine
982265 Nebraska Medical Center
Omaha, NE 68198-2265

Practice Locations:
Omaha, Nebraska
Durham Outpatient Center
For An Appointment Call (402)559-8888
Toll Free 1-800-97-HEART (1-800-974-3278)

Hospital Appointments:
The Nebraska Medical Center

Board Certification:
Cardiovascular Medicine
Clinical Cardiac Electrophysiology 

University of Nebraska Medical Center (Omaha, NE)
Doctorate of Philosophy, 1996
Doctor of Medicine, 1998
Resident - Internal Medicine, 2002
Fellow - Cardiovascular Disease, 2005
Fellow - Electrophysiology, 2006

Clinical Interests:  

Cardiac electrophysiology: Cardiac Electrophysiology isthe science of the mechanisms, functions, and performance of the electrical activities of specific regions of the heart. Dr. Anderson’s specific clinical interests include understanding the aspects and contributing factors involved in atrial and ventricular arrhythmias, as well as in atherosclerosis and ischemic cardiomyopathy. Such arrhythmias areconditions in which the electrical activity of the heart is irregular, is faster or slower than normal and can be life threatening.


Research Interests:

Molecular and cellular immunology is the foundation of Dr. Anderson’s research. Dr. Anderson has a specific focus and interest in innate immunity (preexisting immunity) and how such immune responses contribute to the mechanisms of cardiovascular disease processes. His studies have specifically focused on underlying mechanisms of viral myocarditis, atherosclerotic disease and the impact inflammation has on cardiac rhythm abnormalities. Recent studies have detailed the role of inflammation in arrhythmogenesis and atherosclerosis. Dr. Anderson has also detailed the utility of microbubble technology in the detection and monitoring of vascular inflammation.


Research Support:


AHA Grant-in-Aid:  July 2012 – June 2014

Protein Modification: Immune Sensitization, Cytotoxicity and Cardiovascular Disease.  The overall objective of this proposal is to better understand and evaluate the role of modified proteins in the pathogenesis of atherosclerotic disease in humans. The central hypothesis of this application is that MAA-modified proteins are present early and are central to the progression of atherosclerotic disease, and the immunologic response and phenotype (i.e. IgM, IgG or IgA) is predictive of the clinical progression of atherosclerosis (i.e. CAD progression, stabilization, or regression). 

Role:  Co-Principal Investigator


NIH R01:  March, 2013 - Present

Cardiovascular Inflammation Reduction Trial (CIRT)

Role: Study Site Principal Investigator


St. Jude Medical:  September, 2007 - Present

OPTIMUM Lead Insulation Material Registry

Role: Study Site Principal Investigator


Completed Research Support


AHA - Scientist Development Grant:  January, 2007 – December, 2011

Detection and Monitoring of Vascular Inflammatory Events.  The major goals of this project are to evaluate the mechanisms of perfluorocarbon exposed sonicated dextrose albumin (PESDA) microbubble binding to injured endothelium, and the ability to non-invasively detect, image and monitor injured, inflamed, and dysfunctional endothelium.

Role: Principal Investigator


St. Jude Medical:  December, 2007 – August, 2011

DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation (DETERMINE)

Role: Principal Investigator


Board of Regents of the UNMC:  January, 2007 – June, 2012

Start-up Funds

Detection and Monitoring of Vascular Inflammatory Events

Role: Principal Investigator


NIH Loan Repayment Award:  July, 2007- June, 2009



Publications (1-21)


1.         McManus BM, Chow LH, Wilson JE et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clinical immunology and immunopathology 1993;68:159-69.

2.         Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM. Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. Journal of virology 1996;70:4632-45.

3.         Anderson DR, Carthy CM, Wilson JE, Yang D, Devine DV, McManus BM. Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. Journal of virology 1997;71:8841-5.

4.         Carthy CM, Yang D, Anderson DR, Wilson JE, McManus BM. Myocarditis as systemic disease: new perspectives on pathogenesis. Clinical and experimental pharmacology & physiology 1997;24:997-1003.

5.         Yang D, Wilson JE, Anderson DR et al. In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5' untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers. Virology 1997;228:63-73.

6.         Carthy CM, Granville DJ, Watson KA et al. Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. Journal of virology 1998;72:7669-75.

7.         Yang D, Cheung P, Sun Y et al. A shine-dalgarno-like sequence mediates in vitro ribosomal internal entry and subsequent scanning for translation initiation of coxsackievirus B3 RNA. Virology 2003;305:31-43.

8.         Anderson DR, Tsutsui JM, Xie F, Radio SJ, Porter TR. The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque. Cardiovasc Res 2007;73:597-606.

9.         Anderson DR, Duryee MJ, Anchan RK et al. Albumin-based microbubbles bind up-regulated scavenger receptors following vascular injury. J Biol Chem 2010;285:40645-53.

10.       Duryee MJ, Klassen LW, Schaffert CS et al. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Free Radic Biol Med 2010;49:1480-6.

11.       Anderson DR, Fletcher D, Scherschel JA, Easley AR. Pacemaker-induced inappropriate implantable cardioverter-defibrillator shock: an unusual case of arrhythmia induction. Heart rhythm : the official journal of the Heart Rhythm Society 2011;8:328-30.

12.       Anderson DR, Duryee MJ, Garvin RP, Boska MD, Thiele GM, Klassen LW. A method for the making and utility of gadolinium-labeled albumin microbubbles. Magn Reson Imaging 2012;30:96-103.

13.       Anderson DR, Gillberg JM, Torrey JW, Koneru JN. Lightning induced inappropriate ICD shock: an unusual case of electromagnetic interference. Pacing and clinical electrophysiology : PACE 2012;35:e159-62.

14.       Garvin RP, Duryee MJ, Klassen LW, Thiele GM, Anderson DR. Ultrasound imaging in an animal model of vascular inflammation following balloon injury. Ultrasound Med Biol 2012;38:1552-8.

15.       Khaleel MS, Dorheim TA, Duryee MJ et al. High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure. The Annals of thoracic surgery 2012;93:552-8.

16.       Koepsell SA, Anderson DR, Radio SJ. Parvovirus B19 is a bystander in adult myocarditis. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2012;21:476-81.

17.       Thiele GM, Duryee MJ, Dusad A et al. Citrullinated mouse collagen administered to DBA/1J mice in the absence of adjuvant initiates arthritis. Int Immunopharmacol 2012;13:424-31.

18.       Anderson DR, Poterucha JT, Mikuls TR et al. IL-6 and its receptors in coronary artery disease and acute myocardial infarction. Cytokine 2013;62:395-400.

19.       Jawa RS, Easley AR, Anderson DR. Acute ST segment elevation secondary to acute gastric distention. Journal of Cardiology Cases 2013;8:108-112.

20.       Duryee MJ, Willis MS, Schaffert CS et al. Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis. American journal of physiology Gastrointestinal and liver physiology 2014;306:G208-17.

21.       Dusad A, Duryee MJ, Shaw AT et al. Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant. Immunologic research 2014;58:51-60.